Drugs / REVO-UWD-03
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06653023 | Oct 2024 → Oct 2027 | hepatocellular carcinoma, non-small cell lung carcinoma | Wondercel Biotech (ShenZhen) | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REVO-UWD-03 | “This is an investigator initiated trial to assess the efficacy and safety of a GPC3-targeting CAR-T therapy (REVO-UWD-03) in the HCC and Lung Cancer.” NCT06653023 ↗ |
| Modality | Cell therapy | “GPC3-targeting CAR-T therapy (REVO-UWD-03)” NCT06653023 ↗ |
| Route | Other | “one-time injection of one dose of universal REVO-UWD-03 CAR-T cells” NCT06653023 ↗ |
| Target | GPC3 | “The antigen-binding site of the CAR molecule recognizes GPC3 as the target.” NCT06653023 ↗ |